The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide ...

GLP-1 drugs, synthetic versions of a natural hormone, are revolutionizing weight loss and type 2 diabetes treatment. By ...

Certain medications, such as blood thinners, may interact with omega-3 supplements. Learn more about omega-3 interactions here.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Earlier this year, Meghan revealed that she’d used Mounjaro — among other “lifestyle changes” — to “help” her after her second pregnancy.

In April, the “All About That Bass” singer admitted to using Mounjaro in order “to be the healthiest, strongest version” of ...

Related: 26 Pairs Of Celebrities Who Look Sooo Much Alike, It’s A Little Uncanny This came shortly after Amy detailed her ...

Treatment for obesity in the UK could become a two-tier system where the most vulnerable patients miss out altogether.

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...